The Clinical Need Chemoimmunotherapy (CIT) - combining platinum-based chemotherapy with immune checkpoint inhibitors - is the standard first-line treatment for advanced NSCLC without driver mutations. However, many patients derive limited benefit and current biomarkers like PD-L1 and tumor mutational burden (TMB) have limited predictive power.
What Are Tertiary Lymphoid Structures? Tertiary lymphoid structures (TLS) are ectopic lymphoid aggregates that form in non-lymphoid tissues during chronic inflammation, including within tumors. They contain T cells and B cells organized in a way that resembles lymph nodes and are associated with better antitumor immunity.
Study Approach The researchers analyzed data from three randomized controlled trials (ORIENT-11, OAK, and POPLAR) and The Cancer Genome Atlas to identify TLS gene signatures that specifically predict CIT response in advanced NSCLC.
Key Finding TLS signature 3 was identified as a significant independent predictor of both progression-free survival and overall survival in the CIT setting, working even in PD-L1-negative patients where standard biomarkers fail.
Study Datasets ORIENT-11 (phase 3, sintilimab plus chemotherapy vs. placebo plus chemotherapy, N=397), OAK (phase 3, atezolizumab vs. docetaxel, N=850+), and POPLAR (phase 2, atezolizumab vs. docetaxel) provided the RNA sequencing and clinical outcome data.
TLS Score Calculation Seventeen previously reported TLS gene signatures were scored using single-sample gene set enrichment analysis (ssGSEA) via the GSVA R package. Patients were divided into TLS-high and TLS-low groups based on median score values.
Two-Stage Screening Signatures were first screened in OAK and POPLAR (immunotherapy cohorts) to identify those predictive of immunotherapy outcomes. A key filter excluded signatures with prognostic value in chemotherapy-only arms, ensuring the remaining signatures were immunotherapy-specific rather than general prognostic markers.
Validation in ORIENT-11 Signatures surviving the first screen were then tested in the CIT cohort of ORIENT-11, which included 171 patients with both PD-L1 tumor proportion score data and RNA sequencing. Multivariate Cox analysis and nomogram construction completed the validation.
Survival Benefit In the ORIENT-11 CIT cohort, patients with high TLS signature 3 scores had significantly longer median progression-free survival (9.92 vs. 6.77 months, p=0.001) and overall survival (not reached vs. 17.60 months, p less than 0.001) compared to low-scoring patients.
Independent Predictive Value Multivariate Cox analysis confirmed TLS signature 3 as an independent predictor of PFS (hazard ratio 2.14, p=0.006) and OS (hazard ratio 2.24, p=0.002), meaning its value is not explained by other clinical factors like age, stage, or ECOG performance status.
Nomogram Integration A nomogram integrating TLS signature 3 with eight clinicopathological parameters showed strong discriminative power for predicting 1-year and 2-year OS and 1-year PFS, with high AUC values on receiver operating characteristic curves.
Association with Immune Phenotype High TLS signature 3 correlated with higher PD-L1 expression and hot immune phenotypes (above median ImmuneScore), suggesting that TLS-rich tumors are already immunologically active and primed to respond to immune checkpoint blockade.
The PD-L1 Limitation PD-L1 expression is imperfect as a predictive biomarker for immunotherapy, with a significant proportion of PD-L1-negative patients still responding to ICIs and many PD-L1-positive patients failing to respond.
TLS Adds Predictive Power in PD-L1-Negative Subsets When patients were stratified by PD-L1 status, TLS signature 3 enhanced prediction particularly in PD-L1-negative subsets. This is clinically significant because PD-L1-negative patients are currently the hardest to counsel regarding expected benefit from CIT.
Complementary Biomarkers The combination of PD-L1 testing and TLS signature 3 could identify subsets of patients likely to benefit even in the PD-L1-negative group and help exclude unlikely responders, improving treatment personalization overall.
Biological Rationale TLS facilitate local antigen presentation and B-cell and T-cell cooperation independently of systemic PD-L1-driven immunosuppression. Their presence may represent an alternative pathway to effective antitumor immunity that is not captured by PD-L1 alone.
TLS Formation and Function TLS develop in tumors during sustained inflammation and immune activation. They contain germinal center-like B-cell zones and T-cell zones, facilitating local maturation of tumor-specific immune responses that can be more potent and durable than systemic immune activation alone.
B-Cell and T-Cell Coordination Within TLS, B cells and T cells interact to generate high-affinity antibodies and effector T cells specific to tumor antigens. This organized immune response may amplify the effects of PD-1/PD-L1 blockade by providing a ready-made pool of antitumor effectors.
TLS as Prognostic Markers Across Cancers In NSCLC and other solid tumors, histological TLS presence has been associated with improved survival. The gene signature approach quantifies TLS activity from RNA sequencing data, making it compatible with routine clinical molecular profiling without requiring additional specialized staining.
Relationship to ImmuneScore Patients with high TLS signature 3 scores showed higher ImmuneScore values, confirming that TLS-rich tumors have a globally more inflamed microenvironment, which is the biological basis for their better response to immune-activating therapies.
Study Limitations The analysis was retrospective and limited to NSCLC patients without driver mutations in specific trial contexts. Prospective validation in diverse patient populations with different histologies and treatment regimens is needed.
Mechanistic Validation The biological mechanisms linking TLS signature 3 to CIT response need deeper mechanistic study, including whether specific TLS components (such as germinal center B cells or follicular helper T cells) are particularly important.
Clinical Implementation Pathway To integrate TLS signature 3 into clinical practice, standardized RNA extraction from formalin-fixed paraffin-embedded tumor biopsies and validated scoring cutoffs would need to be established and approved as companion diagnostics.
Combination Strategies Future research should explore whether TLS-inducing therapies - such as radiation or certain immunostimulants - can convert TLS-low tumors to TLS-high status, potentially sensitizing unresponsive patients to CIT in a prospective interventional setting.